Conversely, the most common adverse events of any grade reported during lorlatinib treatment were hypercholesterolemia, hypertriglyceridemia, peripheral oedema, weight increase, peripheral neuropathy, cognitive effects, anemia, hypertension, diarrhea, ALT and AST increase [15]. This evidence concerns the gene GPT and anemia.